Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial

Dermatology: peptide drug development for skin ulcers Chronic leg ulcers result in substantial impairment of patient quality of life with a socioeconomic impact both in terms of medical care and missed work days. A teams led by Hironori Nakagami at Osaka University originally identified a functional...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hironori Nakagami, Ken Sugimoto, Takahiro Ishikawa, Taku Fujimoto, Toshifumi Yamaoka, Misa Hayashi, Eiji Kiyohara, Hiroshi Ando, Yuta Terabe, Yoichi Takami, Koichi Yamamoto, Yasushi Takeya, Minoru Takemoto, Masaya Koshizaka, Tamotsu Ebihara, Ayumi Nakamura, Mitsunori Nishikawa, Xiang Jing Yao, Hideki Hanaoka, Ichiro Katayama, Koutaro Yokote, Hiromi Rakugi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/ea09f00e2134493984d4d6d63a79dba6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea09f00e2134493984d4d6d63a79dba6
record_format	dspace
spelling	oai:doaj.org-article:ea09f00e2134493984d4d6d63a79dba62021-12-02T14:18:31ZPhysician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial10.1038/s41514-018-0021-72056-3973https://doaj.org/article/ea09f00e2134493984d4d6d63a79dba62018-02-01T00:00:00Zhttps://doi.org/10.1038/s41514-018-0021-7https://doaj.org/toc/2056-3973Dermatology: peptide drug development for skin ulcers Chronic leg ulcers result in substantial impairment of patient quality of life with a socioeconomic impact both in terms of medical care and missed work days. A teams led by Hironori Nakagami at Osaka University originally identified a functional peptide, SR-0379, and evaluated the safety and efficacy of SR-0379 for the treatment of leg ulcers in a physician-initiated, first-in-patient, a multi-center, double-blind, randomized clinical study. In the evaluation of efficiency, the skin ulcer reduction rates were improved for the SR-0379 treated groups in a dose-dependent manner, compared for the placebo group with no causal adverse events. Since treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective in this initial clinical trial, the clinical trial on next stage will be designed toward peptide drug development.Hironori NakagamiKen SugimotoTakahiro IshikawaTaku FujimotoToshifumi YamaokaMisa HayashiEiji KiyoharaHiroshi AndoYuta TerabeYoichi TakamiKoichi YamamotoYasushi TakeyaMinoru TakemotoMasaya KoshizakaTamotsu EbiharaAyumi NakamuraMitsunori NishikawaXiang Jing YaoHideki HanaokaIchiro KatayamaKoutaro YokoteHiromi RakugiNature PortfolioarticleGeriatricsRC952-954.6ENnpj Aging and Mechanisms of Disease, Vol 4, Iss 1, Pp 1-7 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Hironori Nakagami Ken Sugimoto Takahiro Ishikawa Taku Fujimoto Toshifumi Yamaoka Misa Hayashi Eiji Kiyohara Hiroshi Ando Yuta Terabe Yoichi Takami Koichi Yamamoto Yasushi Takeya Minoru Takemoto Masaya Koshizaka Tamotsu Ebihara Ayumi Nakamura Mitsunori Nishikawa Xiang Jing Yao Hideki Hanaoka Ichiro Katayama Koutaro Yokote Hiromi Rakugi Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
description	Dermatology: peptide drug development for skin ulcers Chronic leg ulcers result in substantial impairment of patient quality of life with a socioeconomic impact both in terms of medical care and missed work days. A teams led by Hironori Nakagami at Osaka University originally identified a functional peptide, SR-0379, and evaluated the safety and efficacy of SR-0379 for the treatment of leg ulcers in a physician-initiated, first-in-patient, a multi-center, double-blind, randomized clinical study. In the evaluation of efficiency, the skin ulcer reduction rates were improved for the SR-0379 treated groups in a dose-dependent manner, compared for the placebo group with no causal adverse events. Since treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective in this initial clinical trial, the clinical trial on next stage will be designed toward peptide drug development.
format	article
author	Hironori Nakagami Ken Sugimoto Takahiro Ishikawa Taku Fujimoto Toshifumi Yamaoka Misa Hayashi Eiji Kiyohara Hiroshi Ando Yuta Terabe Yoichi Takami Koichi Yamamoto Yasushi Takeya Minoru Takemoto Masaya Koshizaka Tamotsu Ebihara Ayumi Nakamura Mitsunori Nishikawa Xiang Jing Yao Hideki Hanaoka Ichiro Katayama Koutaro Yokote Hiromi Rakugi
author_facet	Hironori Nakagami Ken Sugimoto Takahiro Ishikawa Taku Fujimoto Toshifumi Yamaoka Misa Hayashi Eiji Kiyohara Hiroshi Ando Yuta Terabe Yoichi Takami Koichi Yamamoto Yasushi Takeya Minoru Takemoto Masaya Koshizaka Tamotsu Ebihara Ayumi Nakamura Mitsunori Nishikawa Xiang Jing Yao Hideki Hanaoka Ichiro Katayama Koutaro Yokote Hiromi Rakugi
author_sort	Hironori Nakagami
title	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
title_short	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
title_full	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
title_fullStr	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
title_full_unstemmed	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
title_sort	physician-initiated clinical study of limb ulcers treated with a functional peptide, sr-0379: from discovery to a randomized, double-blind, placebo-controlled trial
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/ea09f00e2134493984d4d6d63a79dba6
work_keys_str_mv	AT hironorinakagami physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT kensugimoto physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT takahiroishikawa physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT takufujimoto physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT toshifumiyamaoka physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT misahayashi physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT eijikiyohara physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT hiroshiando physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT yutaterabe physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT yoichitakami physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT koichiyamamoto physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT yasushitakeya physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT minorutakemoto physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT masayakoshizaka physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT tamotsuebihara physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT ayuminakamura physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT mitsunorinishikawa physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT xiangjingyao physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT hidekihanaoka physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT ichirokatayama physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT koutaroyokote physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial AT hiromirakugi physicianinitiatedclinicalstudyoflimbulcerstreatedwithafunctionalpeptidesr0379fromdiscoverytoarandomizeddoubleblindplacebocontrolledtrial
_version_	1718391640388796416

Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial

Ejemplares similares